ReviewTargeting IL-17 in psoriasis: From cutaneous immunobiology to clinical application
Highlights
► There has been progress in dissecting the genetics and immunobiology of psoriasis. ► TH17 and IL-17 play an important role in the pathogenesis of psoriasis. ► Biologics that target the IL-17 axis are well tolerated and effective in treating psoriasis. ► Disrupting the TH17/IL-17 axis may be a strategy to treat autoimmune diseases.
Introduction
Psoriasis vulgaris is a chronic, immune-mediated inflammatory skin disease associated with complex genetic susceptibility [1]. The estimated prevalence of psoriasis in the United States is 3%, with approximately 17% of these patients having moderate-to-severe plaque psoriasis [2]. Up to 30% of psoriasis patients have psoriatic arthritis [3]. The hallmark of psoriasis is characterized by cutaneous inflammation and keratinocytes hyperproliferation, currently hypothesized to be the consequence of pathologic innate and adaptive immune activation in genetically prone individuals.
Recent studies to dissect the molecular basis of psoriasis have led to a better understanding of this complex disease. Although the primary feature of psoriasis is excessive keratinocyte hyperproliferation, an immune role was suggested by the identification of activated T cells in the dermis and epidermis, an improved response of psoriasis patients to anti-T cell therapies and the resolution of lesions in patients with psoriasis after bone marrow transplant [1], [4]. Further evidence emerged from the clinical efficacy of cyclosporine, a calcineurin inhibitor, which targets the transcription factor nuclear factor of activated T cell (NFAT), and is critical for T cell activation and function [5]. These observations highlighted the contribution of T cells in a disease of excessive epidermal hyperplasia.
Section snippets
Psoriasis genetics
From recent studies, it is clear that numerous components of the immune system are defective in psoriasis, belonging to both the innate and adaptive immune system. Thus, psoriasis is a complex disease characterized by a complex interplay between multiple risk genes, environmental factors and various cells involved in innate and adaptive immunity [1], [6]. Recently, accumulating evidence shows that psoriasis has biased immune alterations, affecting the TH17/IL-23 and NF-κB signaling pathways as
Immune dysfunction in psoriasis
Studies focused on the role of the microenvironment in the skin of psoriasis lesions have revealed additional cellular and cytokine abnormalities of the immune system [25]. The ability to distinguish subtypes of immune cells has identified different DC populations that mediate response to antigen, and lymphocyte subpopulations in the skin that play a role in psoriasis [26]. From these findings, insight into the molecular cellular mechanisms of psoriasis has emerged to reveal the disordered
Role of dendritic cells in psoriasis
DCs are professional antigen presenting cells that play an essential role in regulating the balance between immunity and immunological tolerance [60]. Recent studies have demonstrated that DCs play an important role in psoriasis and may be the primary cell type that drives TH17 differentiation in psoriasis through the production of IL-6 and IL23, which are required for differentiation to the TH17 subtype as well as the proliferation and stabilization of TH17 cells, respectively [1], [50], [61],
Therapeutic agents in psoriasis: targeting IL-17
The application of human monoclonal antibodies to specific targets has been a successful approach in treating autoimmune disease. Psoriasis has been an ideal disease to study the critical role of cytokine pathways that become dysregulated, since clinical responses can be monitored and quantitated visually with the disappearance of psoriasis lesions.
With the identification of various cytokines abnormally expressed in psoriasis, a challenge is to identify cytokines that are “driver” cytokines or
Conflict of interest statement
Henry Wong received honorarium from Amgen and grant as an investigator with Amgen, Janssen, Abbott Labs and Celgene.
Maria Ariza received grant support from the National Psoriasis Foundation.
References (98)
- et al.
Psoriasis: epidemiology
Clin. Dermatol.
(2007) - et al.
Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A
J. Invest. Dermatol.
(2002) - et al.
Psoriasis—as an autoimmune disease caused by molecular mimicry
Trends Immunol.
(2009) - et al.
Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris
J. Invest. Dermatol.
(2001) - et al.
Psoriasis and other complex trait dermatoses: from Loci to functional pathways
J. Invest. Dermatol.
(2012) - et al.
Protective effect of human endogenous retrovirus K dUTPase variants on psoriasis susceptibility
J. Invest. Dermatol.
(2012) - et al.
A human endogenous retrovirus K dUTPase triggers a TH1, TH17 cytokine response: does it have a role in psoriasis?
J. Invest. Dermatol.
(2011) - et al.
Resident and “inflammatory” dendritic cells in human skin
J. Invest. Dermatol.
(2009) - et al.
Circulating Th17, Th22, and Th1 cells are increased in psoriasis
J. Invest. Dermatol.
(2010) - et al.
The IL-23/Th17 axis in the immunopathogenesis of psoriasis
J. Invest. Dermatol.
(2009)
Interleukin-23 drives intestinal inflammation through direct activity on T cells
Immunity
gammadelta T cells: an important source of IL-17
Curr. Opin. Immunol.
Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation
Immunity
Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells
J. Invest. Dermatol.
cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus
J. Biol. Chem.
Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus
J. Biol. Chem.
Harnessing dendritic cells in inflammatory skin diseases
Semin. Immunol.
Th17 cell differentiation: the long and winding road
Immunity
Transcriptional regulation of Th17 cell differentiation
Semin. Immunol.
Role of dendritic cells in benign and malignant lymphocytic infiltrates of the skin
Dermatol. Clin.
The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients
J. Invest. Dermatol.
Prominent production of IL-20 by CD68 +/CD11c + myeloid-derived cells in psoriasis: gene regulation and cellular effects
J. Invest. Dermatol.
Immunobiologics in the treatment of psoriasis
Clin. Immunol.
Psoriasis—recent advances in understanding its pathogenesis and treatment
J. Am. Acad. Dermatol.
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase i, randomized, placebo-controlled trial
J. Invest. Dermatol.
Evaluation of the IRF-2 gene as a candidate for PSORS3
J. Invest. Dermatol.
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes
Am. J. Hum. Genet.
Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans
J. Invest. Dermatol.
Psoriasis susceptibility locus on 18p revealed by genome scan in Finnish families not associated with PSORS1
J. Invest. Dermatol.
Pathogenesis of human systemic lupus erythematosus: recent advances
Trends Mol. Med.
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells
J. Invest. Dermatol.
Psoriasis
Annu. Rev. Pathol.
Psoriatic arthritis: update on pathophysiology, assessment and management
Ann. Rheum. Dis.
Getting under the skin: the immunogenetics of psoriasis
Nat. Rev. Immunol.
Psoriasis
N. Engl. J. Med.
Th17 response and inflammatory autoimmune diseases
Int. J. Inflam.
New insights into the pathogenesis and genetics of psoriatic arthritis
Nat. Clin. Pract. Rheumatol.
Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study
Br. J. Dermatol.
An investigation of antistreptococcal antibody responses in guttate psoriasis
Arch. Dermatol. Res.
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Nature
Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8
J. Exp. Med.
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2
Nat. Genet.
Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris
J. Immunol.
Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris
Eur. J. Immunol.
T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells
Eur. J. Immunol.
IL-17-producing CD8 + T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines
J. Leukoc. Biol.
Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis
PLoS One
Cracking the cytokine code in psoriasis
Nat. Med.
Cited by (47)
Breakthroughs and bottlenecks of psoriasis therapy: Emerging trends and advances in lipid based nano-drug delivery platforms for dermal and transdermal drug delivery
2023, Journal of Drug Delivery Science and TechnologyClinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis
2017, Actas Dermo-SifiliograficasCitation Excerpt :Psoriasis is an immune-mediated disease initially considered to be a result of a Th1 response with the signature cytokines INF-γ and IL-12. However, recent studies investigating the molecular basis of psoriasis identified the key role of the adaptive Th17 cells.5 The actual model of immunopathogenesis (Fig. 1) proposes that an unknown antigen or environmental trigger activates macrophages, natural killer (NK) T cells and plasmacytoid dendritic cells (DCs) to secrete TNF-α, INF-α, INF-γ, IL-1β and Il-6, which trigger myeloid DCs activation.
Natural killer cells from psoriasis vulgaris patients have reduced levels of cytotoxicity associated degranulation and cytokine production
2017, Clinical ImmunologyCitation Excerpt :This finding that NK cell activity is reduced in both psoriasis and atopic dermatitis patients is intriguing given the differences in the pathogeneses of these diseases. While both diseases are characterised by recurring bouts of skin inflammation, atopic dermatitis is considered to be a Th2 disease, while psoriasis has greater involvement of Th1 and Th17 cells, with IL-17 believed to play a key role [66]. These diseases have very different cytokine environments that are likely to have differing effects on NK cells.
Efficacy and safety of netakimab therapy in patients with moderate to severe psoriasis in real clinical practice
2023, Vestnik Dermatologii i Venerologii